Conduit Rebrands As CDT Equity To Drive AI-Led Drug Development And Explore Crypto Strategy

Conduit Pharmaceuticals has announced its intent to rebrand as CDT Equity Inc., reflecting its evolution into a data-driven biotech development platform. The rebranding aligns with the company’s expanded mission of accelerating therapeutic innovations through AI integration, solid-form chemistry, and asset repositioning. Originally founded to develop therapeutic assets, CDT now focuses on enhancing undervalued clinical-stage compounds through scientific and strategic innovation.

"Operating with a lean, disease-agnostic model, CDT Equity Inc. prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies. Looking ahead, we are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation," said Dr. Andrew Regan, Chief Executive. 

CDT’s pipeline targets a broad range of therapeutic areas, including inflammatory and autoimmune disorders, idiopathic male infertility, dermatology, and animal health. By using advanced solid-form technologies developed in Cambridge, CDT has succeeded in extending drug patent life by up to 20 years. Their collaboration with Sarborg enables AI-driven disease mapping and repurposing of compounds, which has led to new combination patent filings and preclinical models without human intervention.

In parallel, CDT’s partnership with Manoira expands its reach into animal health, providing cost-effective insights while retaining exclusive rights to human data. This dual-market approach enhances their human drug development strategy and opens new revenue opportunities. Additionally, CDT is exploring the integration of cryptocurrency into its treasury strategy, aiming to leverage the digital asset space for long-term strategic and financial benefits.